PKP-029 Pharmacogenetic study of the influence of polymorphisms in the tnfr1a and fas genes on the response to rituximab and chemotherapy in follicular lymphoma patients

BackgroundInterindividual variability in treatment response may be associated with the presence of gene polymorphisms. Monoclonal antibodies seem to exert, at least partly, their mechanism of action by inducing apoptosis in antigen expressing cells. TNFR1A and FAS are receptors involved in the induc...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A191-A191
Main Authors: Cívicos, MDR Gutiérrez, Zamora, P Conesa, Morales, I Español, Maestre, D Gutiérrez-Meca, Viney, AC, García, I Muñoz, Lagunar, MH García, Márquez, A García, Bautista, R Guerrero, Villanueva, E Ferris
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Chemotherapy
Genes
Lymphoma
Polymorphism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundInterindividual variability in treatment response may be associated with the presence of gene polymorphisms. Monoclonal antibodies seem to exert, at least partly, their mechanism of action by inducing apoptosis in antigen expressing cells. TNFR1A and FAS are receptors involved in the induction of apoptosis by the extrinsic pathway. Polymorphisms in these genes may be implicated in the response to rituximab, a monoclonal antibody targeting neoplastic B cells expressing CD20 antigen.PurposeTo assess the influence of the functional gene polymorphisms rs767455 TNFR1A and rs1800682 FAS on response to treatment with rituximab associated with the chemotherapy CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) in patients with follicular lymphoma (FL).Material and methodsRetrospective observational study including a cohort of FL patients treated with rituximab in combination with firstline CHOP chemotherapy, recruited from two university hospitals. The clinical response was assessed after the fourth cycle and when treatment was completed. Response criteria used were proposed by the International Working Group: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), considered SD and PD for non-responders (NR). Gene polymorphisms were determined by fluorescent allelic discrimination. Statistical analysis was performed using statistical package SPSS 22.0.Results78 patients were included (64% men, average age 50.9 ± 13.1 years). Median number of rituximab cycles was 6.4 ± 1.2. The pharmacogenetic study was performed in 59 patients at the fourth cycle and in 76 (for rs767455) and 75 (for rs1800682) at the end of treatment. Distribution for response/genotypes were as follows: • after the fourth cycle: NR (TC=3 (100%)), PR (CC=3 (7.7%), TC=18 (46.2%), TT=18 (46.2%)), CR (CC=3 (17.6%), TC=9 (52.9%), TT=5 (29.4%)) (polymorphism rs767455); NR (CC=2 (66.7%), TC=1 (33.3%)), PR (CC=12 (30.8%), TC=17 (43.6%), TT=10 (25.6%)), CR (CC=3 (17.6%), TC=12 (70.6%), TT=2 (11.8%)) (polymorphism rs1800682); • when treatment was completed: NR (TC=3 (100%)), PR (CC=3 (16.7%), TC=6 (33.3%), TT=9 (50.0%)), CR (CC=4 (7.3%), TC=32 (58.2%), TT=19 (34.5%)) (polymorphism rs767455); NR (CC=2 (66.7%), TC=1 (33.3%)), PR (CC=4 (23.5%), TC=9 (52.9%), TT=4 (23.5%)), CR (CC=15 (27.3%), TC=26 (47.3%), TT=14 (25.5%)) (polymorphism rs1800682) No statistically significant differences were found between genotypes (rs767455; rs1800682) and clinical re
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2016-000875.432